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Abstract
Poorly water soluble drugs comprise the majority of new drug molecules. Nanoparticle 
agglomerates, called NanoClusters, can increase the dissolution rate of poorly soluble compounds 
by increasing particle surface area. Budesonide and danazol, two poorly soluble steroids, were 
studied as model compounds. NanoCluster suspensions were made using a Netzsch MiniCer 
media mill with samples collected between 5 and 15 hours and lyophilized. DSC and PXRD were 
used to evaluate the physicochemical properties of the powders and BET was used to determine 
surface area. SEM confirmed NanoClusters were between 1 and 5 μm. NanoCluster samples 
showed an increase in dissolution rate compared to the micronized stock and similar to a dried 
nanoparticle suspension. BET analysis determined an increase in surface area of 8 times for 
budesonide NanoClusters and 10 to 15 times for danazol NanoClusters compared to micronized 
stock. Melting temperatures decreased with increased mill time of NanoClusters by DSC. The 
increased surface area of NanoClusters provides a potential micron-sized alternative to 
nanoparticles to increase dissolution rate of poorly water soluble drugs.
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 1. Introduction
In a quest to identify highly potent and selective drugs, active pharmaceutical ingredients 
that have less desirable pharmaceutical properties are being developed1,2,3,4,5. Many of the 
compounds are BCS class II (high permeability but low solubility) or IV (both low 
permeability and solubility). BCS class II compounds can be particularly difficult to 
formulate6. In some instances, poor solubility and/or slow dissolution leads to low oral 
bioavailability, which can reduce their efficacy1,3,7,9. Oral administration is the most 
desirable route of administration given its high patient compliance and safety margins2,10. 
The fact that up to 70% of newly developed oral drugs along with 40% of drugs currently 
marketed are poorly water soluble presents a formidable challenge1,2,11.
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Since many active pharmaceutical agents dissolve slowly in water, there have been new 
strategies developed to increase dissolution rate4,5. Formulation strategies varying excipients 
or other compounds can be used to enhance dissolution. Dissolution rate can be improved by 
increasing tablet disintegration or improving drug particle wetting7,9,12. Some strategies use 
polymer systems that dissolve with time to create a porous network of channels throughout 
the dosage form to increase the amount of water available to contact the poorly water soluble 
drug surface13,14. Other methods use excipients to create emulsions,11,15,16,17, combine 
liquids with powder forming liquisolid samples18,19, or to add wetting agents to improve 
disintegration of the solid dosage form7,9,12,20.
Besides different formulation strategies, there has also been a surge in technologies to 
increase dissolution by manipulating the size of drug particles20. There are bottom-up 
methods including precipitation, solid dispersions5,7,21, spray drying and spray freezing into 
liquid4,5,16,22,23,25 as well as top-down methods such as homogenization and 
milling3,16,25,26. Some bottom-up methods including precipitation can involve cosolvents18, 
which add the burden of solvent removal and disposal after processing and before use by 
patients27. Spray drying allows more precise control of particle size but may be an issue if 
the product is thermally labile4. Bottom-up methods including some precipitation methods 
and spray freezing into liquids can produce amorphous compounds. Amorphous compounds 
tend to be more intrinsically unstable than crystalline forms and can spontaneously revert to 
a lower energy crystalline form. Of course, changes in drug morphology over time are not 
desirable and may alter the properties of the drug22. Finally, bottom-up methods are 
typically more difficult to scale up to the large amounts needed in the pharmaceutical 
industry, which may be less desirable26.
Top-down approaches include methods such as milling25 and homogenization26. Milling can 
be further broken down into both dry and wet milling28. Dry milling includes jet milling, 
which has the tendency to create more surface defects, potentially increasing the associated 
electrostatics29. Wet milling can reduce surface defects by allowing some recrystallization to 
occur30. One such top down technology is called NanoCrystal®, where the drug compound 
is milled with surfactants to create and maintain individual nanoparticles in an effort to 
achieve more rapid dissolution11,31,32. The strategy behind many of these techniques is to 
decrease particle size to increase surface area,16,24. One potential issue with using 
surfactants is that surfactants can have side effects in patients24.
Overall many of these methods intend to decrease particle size1,18,33, but often the corollary 
of increased surface area is presupposed and not quantified33. This paper will analyze two 
poorly water soluble steroids, budesonide34 and danazol35 as model compounds to test 
increased dissolution by forming nanoparticle agglomerates, called NanoClusters through 
wet milling. Since they are agglomerates, NanoClusters36,37,38 offer both micronized 
particle and nanoparticle properties. NanoClusters could, therefore, provide an excipient free 
alternative to strategies such as NanoCrystal® technology31,32. Here, we investigate if 
increased surface area of NanoClusters improves dissolution of poorly water soluble 
compounds.
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 2. Materials and methods
 2.1. Materials
Budesonide micronized stock (Bud) was obtained from Sicor de Mexico, Lerma, Mexico. 
Danazol micronized stock (Dan) was purchased from Voigt Global Distribution Inc, 
Lawrence, Kansas. Pluronic® F-68 was obtained from BASF, Florham, New Jersey. All 
water used was deionized (DI) water from a Labconco Pro PS system. All other chemicals 
and materials including acetonitrile, sodium lauryl sulfate, 0.1 μm pore size Whatman nylon 
filters, and Beckton Dickinson 3 mL plastic syringes, were purchased from Fisher Scientific.
 2.2. NanoCluster synthesis by wet milling
Budesonide and danazol NanoCluster suspensions were synthesized using a Netzsch 
MiniCer Media Mill (NETZSCH Fine Particle Technology, LLC, Exton, PA). The mill was 
run with several predetermined process parameters including a grinder speed of 2772 rpm, a 
chiller unit temperature between 6 and 8°C, a mill temperature of 18°C, and a mill pressure 
of under 2 bar. The drug suspensions were milled using 200 μm YTZ® (yttrium treated 
zirconium) grinding media from Tosoh Corp., Tokyo, Japan.
Budesonide and danazol micronized stock were each suspended in nitrogen purged DI water 
to reduce the likelihood of oxidation during milling. Either drug (3.25 g) was added to 390 
mL of nitrogen-flushed DI water. The powder was wetted by introducing drug slowly, while 
continuously stirring, and NanoClusters were produced by grinding with no added 
excipients. Both budesonide and danazol samples were collected at 5, 10, and 15 hours. 
Thirty mL of the suspension was collected at each time point with 10 mL deposited into 
three 20 mL antistatic vials. Upon completion, the remaining suspension was collected into 
20 to 25 antistatic vials. Nanoparticle suspension samples were produced by milling in 0.1% 
(w/v) Pluronic® F-68 solution33,42 until a mean diameter of 150 to 200 nm was achieved. 
Samples were immediately frozen in liquid nitrogen and maintained at a temperature of 
−80 °C. Samples were lyophilized for 72 hours at a temperature of −72 °C at a vacuum of 
<300 millitorr (VirTis Feezemobile-12XL, The Virtis Company, NY).
 2.3. NanoCluster particle size and morphology
A LEO 1550 field emission scanning electron microscope (SEM) was used to evaluate the 
particle size and morphology of the NanoCluster powder compared to the micronized stock 
and to the nanoparticle suspension39. Samples were sputter-coated with gold for 3 min. 
Dynamic light scattering (DLS) (Brookhaven Instruments Corp., ZetaPALS, Holtsville, NY) 
was performed to determine individual particle size comprising the agglomerates39. To 
better estimate the size of the nanoparticles and not the agglomerates, 0.5 mL of the milled 
suspension was diluted to 10 mL with 0.1% (w/v) Pluronic® F-68 solution. The suspension 
was then sonicated for 30 s at an amplitude of 20% with a microtip probe sonicator (Fisher 
Scientific, Sonic Dismembrator, Pittsburgh, PA) prior to analysis. The agglomerated 
NanoClusters were sized using micro flow imaging (MFI) (DPA 4100/4200 from Brightwell 
Technologies, Inc. Ottawa Canada) with Flow Microscope MVSS version 2 software. 
Samples were suspended in 0.01% sodium lauryl sulfate to ensure particles did not stick in 
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the flow cell while maintaining a particle concentration of approximately 900000 
counts/mL.
 2.4. Surface area determination using BET
Surface area was determined via the BET (Brunauer, Emmett and Teller) Theory using a 
TriStar 3000, Micrometrics Gemini 2375 V 5.01, Norcross, GA connected to a computer 
running Star Driver (version 2.03). The surface area for the NanoClusters was measured for 
all powders by nitrogen adsorption and compared to that of the micronized stock drug and 
nanoparticle suspension. Prior to surface area measurement, a known mass of the sample 
powder (120 ± 30 mg) was placed in a sample tube. Another reference tube filled with 3 mm 
spherical glass beads was used as a reference. Liquid nitrogen was used to maintain the 
sample and reference tube at low temperature to yield an accurate determination of surface 
area17.
 2.5. Determination of degradation using HPLC-UV
The chemical stability of the NanoCluster powder was determined by chromatographic 
analysis. The HPLC-UV system consisted of a Shimadzu CBM-20A system controller, 
LC-10AT solvent delivery pump, SPD-10A UV detector, and SIL-10AxL autoinjector. 
Chromatograms were acquired and analyzed using Shimadzu Class vp 7.4 software. A 
Kromasil C8 column (100 x 4.6 mm) was used for budesonide separation, while a Hypersil 
C18 (100 x 4.6 mm) was used for danazol. The powders used an isocratic system with a 
mobile phase of 55/45 acetonitrile/water at a flow rate of 1.1 mL/min. Detection was 
performed at 244 nm for budesonide, and danazol was detected at 288 nm. Samples of 
NanoClusters and micronized stock powder were made at a concentration of 250 μg/mL in 
acetonitrile and 30 μL was injected. The spectra showed a characteristic budesonide peak 
with a retention time of 4.55 min and a degradant peak with a retention time of 2.72 min. 
Danazol had a retention time of 9.2 min and a degradation peak at 6.35 min. Percent 
degradation was determined using the peak area of the degradant relative to the total peak 
area37,38,39.
 2.6. NanoCluster crystallinity determination using powder x-ray diffraction (PXRD)
PXRD was used to determine the relative crystallinity of the NanoClusters compared to the 
miconized stock material. PXRD was performed using a monochromated CuKα radiation (λ 
= 1.54178 Å) on a Bruker Proteum Diffraction System equipped with Helios multilayer 
optics, an APEX II CCD detector or a Platinum 135 CCD detector and a Bruker MicroStar 
microfocus rotating anode x-ray source operating at 45 kV and 60 mA. The powder sample 
was suspended in Paratone N oil then loaded on a nylon loop. The loop was then loaded on 
the goniometer where either 3 or 2, 180° 1 minute scans (based on the detector) were taken 
using the Bruker Apex2 V2010.3-0 software package. Scans were taken at 30°, 60° and 90° 
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with the detector 50.0 mm away. The patterns were analyzed using the Bruker EVA powder 
diffraction software package version 13.039.
 2.7. NanoCluster analysis using differential scanning calorimetry (DSC)
DSC was performed to determine any thermal transitions of the NanoClusters compared to 
the micronized drug. DSC was performed on a Q100 DSC (TA Instruments). Approximately 
3 to 5 mg of each sample was loaded into an aluminum hermetic pan. DSC was performed 
from 40 °C to 300 °C using a ramp of 10 °C per min for both budesonide and danazol39.
 2.8. Dissolution of NanoCluster dry powder
Dissolution was performed using a Distek 2100A dissolution tester with temperature control 
system. Dissolution medium was 900 mL of 0.25% sodium lauryl sulfate solution. 
Approximately 25 mg of powder was wetted then added to the dissolution vessels 
mimicking the USP Type II paddle method (37 °C ± 0.5 °C, paddle speed of 75 rpm, and 
paddle depth of 2.5 mm from the bottom of the vessels). Three mL samples were taken at 5, 
10, 15, 20, 30, 45, and 60 minutes with dissolution medium added to replace the sample 
volume. Samples were immediately filtered using a 0.1 μm nylon filter to remove any 
undissolved drug particles and were then analyzed using HPLC-UV under the same 
conditions specified to determine chemical degradation29,40.
 3. Results and discussion
 3.1. Wet milling created nanoparticle agglomerates
The wet milling process created nanoparticle agglomerates, called NanoClusters, which 
were confirmed using SEM39. There was a definitive decrease in particle size due to milling 
when compared to the stock micronized drug particles (Fig 1 and 2). The NanoClusters were 
in the size range of 1 to 4 μm and were composed of agglomerated drug nanoparticles 
approximately 200 nm in size. The micronized stock drugs were approximately 2 to 10 μm 
for both budesonide and danazol and were solid crystals. MFI confirmed that the typical 
median size or D50 of the NanoClusters was between 1 and 2 microns and decreased with 
milling time. The micronized stock was over 2 microns in size, slightly larger than both 
budesonide and danazol NanoClusters (Table 1 and 2). Samples were tested over a period of 
two years with a negligible change in particle size in both DLS and MFI (Table 1 and 2).
The NanoClusters had a different particle morphology compared to the other samples (Fig 
1B–D and 2B–D). The NanoClusters were somewhat spherical or irregular microparticles 
formed by agglomerated 200 – 400 nm nanoparticles with some cavities and voids left 
between the nanoparticles. The nanoparticle suspension samples were mostly individual 
nanoparticles stabilized by Pluronic® F-68 during synthesis (Fig 1E and 2E). Small 
agglomerates in the nanoparticle sample formed as a result of the drying process during 
lyophilization. The nanoparticle suspension samples had particle distribution mainly below 1 
μm with a mean size of 250 nm with some reversible agglomeration occurring after 
lyophilization.
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After an initial period of size reduction, the particles in the agglomerated NanoClusters 
slightly increased in size by approximately 70 nm with increasing milling time (Table 1 and 
2). There are a couple of possible explanations for this increase in particle size. One would 
be that even though the agglomerates are sonicated in 0.1% (w/v) Pluronic® F-68 for sizing, 
the individual particles are still partially agglomerated together due to high surface energy. 
Individual particles are not being measured, just smaller agglomerates29. It is important to 
note that without the sonication step, the NanoClusters remained as agglomerated 
nanoparticles above the limits of DLS. Even in a dilute surfactant solution, the NanoClusters 
need to be subjected to intense ‘shear’ to disrupt the agglomerated microparticles to generate 
the individual nanoparticles. Another less likely explanation is the crystals of the drug are 
fractured to generate the decreased particle size, and over time crystal healing or Ostwald 
ripening occurs increasing the particle size29,20. This hypothesis was not supported, 
however, by SEM observations. SEM micrographs do give information about the 
morphology of the NanoClusters. The NanoClusters have voids between the nanoparticles 
(Fig 1 and 2), due to the agglomeration process which forms the particles. These voids are 
part of the reason for the increase in surface area facilitating an increased dissolution rate.
 3.2. Increase in surface area and not a change in drug properties enhanced dissolution
The increased dissolution rate was a direct result of the increase in surface area of the 
NanoCluster samples. The micronized stock materials had surface areas around 3 to 4 m2/g, 
while the NanoCluster samples had surface areas of 8 times more for budesonide and even 
10 to 15 times more for danazol (Table 1 and 2). There was no discernible trend for the 
increased surface area for budesonide as the milled NanoCluster samples all had 
approximately 33 m2/g (Table 1). Danazol, however, showed a considerable trend with 
longer mill times. There was an increase of approximately 11 m2/g for each 5 hour increase 
in mill time (Table 2) corresponding to an 8, 11, and 14 fold increase for the NanoCluster 
samples milled for 5, 10, and 15 hours, respectively.
The nanoparticle suspension for both compounds when run through BET surface area 
analysis gave a measured value of approximately 10 m2/g. This value does not agree with 
the surface area of 35 m2/g calculated from measured particle hydrodynamic radius 
suggesting that the Pluronic® stabilizer may have caused an anomalous reading. Comparing 
the calculated value with the milled NanoCluster samples shows that the surface area of the 
nanoparticle samples would match the respective budesonide NanoCluster samples and the 
10 hour milled danazol NanoCluster sample. A calculation of nanoparticle suspension 
surface area (from dissolution data) is similar to the surface area of NanoClusters 
determined by BET (Table 1 and 2), which also supports the similar dissolution kinetics 
observed44.
The increase in surface area would account for the increase in dissolution, but there were 
some observed differences in the trends. For budesonide, the surface area of all the milled 
NanoCluster samples and the nanoparticle suspension, were similar yet there were some 
small differences in the dissolution profiles. For danazol, there was a marketed difference in 
surface area between the milled NanoCluster samples, yet there was no discernible 
difference in the dissolution profiles. It is possible that attaining a ‘threshold’ surface area is 
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important. In other words, increasing surface area by at least 7 times compared to the 
micronized stock diminishes differences for these particular drugs as the surface area is 
further increased. Another explanation could be local saturation. After a 7 to 8 fold increase 
in surface area, dissolution may not increase due to a lack of local sink conditions (i.e. 
within the NanoCluster) or some other factor specific to these two compounds. As 
mentioned before, concentration gradients from the surface of the individual nanoparticles 
may impinge (darker regions in Fig 8 as dissolution profiles overlap) yielding a more 
complicated dissolution profile than predicted by changes in surface area alone31. An 
enhancement would still be seen in dissolution, but that enhancement may not be as 
extensive as expected. Finally, it is also possible that these two compounds may not exhibit a 
strict surface area correlation39.
HPLC-UV analysis of NanoClusters showed that there was relatively little degradation even 
at extended milling times (Table 1 and 2)39. The percent degradation increased from 0.18% 
to 0.81% for budesonide and 0.21% to 1.29% for danazol as milling time progressed from 5 
– 15 hours. The degradation products were determined by comparing the HPLC curves of 
the micronized stock and the milled products (Fig 9 and 10). Peaks were clearly separated 
allowing use of this approach. Previous literature results suggest the expected degradant 
products for budesonide to include 16α-hydroxyprednisolone and 6β-hydroxybudesonide34 
and for danazol ethisterone and 2-hydroxymethyl ethisterone35. These compounds are 
formed as hydrophobic portions of the parent compound are removed thereby decreasing 
hydrophobicity. The removal of these hydrophobic regions increases the exposure of more 
polar heteroatoms. These two chemical differences explain why the new peaks associated 
with degradation products have eluted earlier in the reverse phase35,34.
DSC thermograms illustrate the samples maintained the same relative crystallinity39. A 
decrease was seen in the melting temperature of both danazol and budesonide NanoCluster 
samples compared to the micronized stock material (Table 1 and 2). A decrease in melting 
temperature is commonly observed as particle size decreases. Since the NanoCluster 
samples are composed of nanoparticle agglomerates and each agglomerated microparticle 
has multiple crystals, heat is transported quickly in individual nanoparticles resulting in the 
decreased melting temperature as milling time increased. The nanoparticle powders also had 
decreased melting temperatures compared to the micronized stock material and had a similar 
melting temperature to the NanoCluster samples milled for 5 hours. The fact that the 
nanoparticle powder had a similar melting temperature to the NanoCluster samples and that 
the nanoparticle samples were milled for a short time is further evidence that the samples 
have not changed crystalline form to either an amorphous solid or different polymorph. The 
shape of the DSC curves provided further evidence as well. The curves have a very definitive 
and sharp peak expected for crystalline drugs (Fig 3 and 4).
The PXRD data complements the DSC data and lends further credence to the idea that there 
was no change in crystallinity that caused the increase in dissolution rate (Fig 11 and 12)39. 
For budesonide, there was a decrease in peak intensity of the NanoCluster samples 
compared to the micronized stock budesonide. There was a small decrease in resolution 
from the micronized material as well compared to the NanoClusters, but the NanoClusters 
had a higher peak intensity compared to the nanoparticle sample. There was no trend in peak 
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intensity that correlated to increases in mill time for the budesonide NanoClusters. The 
decrease in peak intensity seen particularly in Fig 12 can potentially be due to the nanosizing 
of the drug crystals. Nanosizing can produce differences in the xray scattering so the 
agglomerated particles can have subtle differences in scattering that may decrease intensity 
but peak position is more determinant. Differences due to nanosizing were also seen in the 
DSC thermograms, which provide further evidence that the decrease in signal intensity was 
not due to a change from crystalline to amorphous.
The danazol samples had a slight difference from the budesonide samples. Similar to 
budesonide, the micronized danazol sample had a higher peak intensity and resolution as 
compared to the NanoClusters. The peak height in danazol NanoCluster samples did appear 
to decrease in intensity with increased mill time. The 5 hour milled NanoCluster sample had 
a higher intensity than the nanoparticle suspension sample but the 10 hour and 15 hour 
milled samples had a lower peak intensity on average.
There was an interesting repeating theme as the nanoparticle samples had very similar 
properties to the 5 hour milled NanoCluster samples or between the 5 and 10 hour milled 
NanoCluster samples. For example, even though the nanoparticle samples were milled for 
less than half the time of the 5 hour milled NanoCluster sample, all the samples had similar 
melting temperatures and PXRD patterns for both budesonide and danazol. Practically 
speaking, shorter mill times facilitate scaling to larger amounts.
 3.3. NanoClusters enhanced dissolution rate
NanoCluster samples had increased dissolution rates as compared to the micronized stock 
drugs (Fig 5 and 6). Both budesonide and danazol micronized material gradually dissolved 
over the one hour study. Approximately 55% to 70% of the micronized drugs were dissolved 
in the first 5 minutes. Micronized budesonide and danazol samples required approximately 
30 and 45 minutes, respectively, to dissolve completely. The nanoparticle suspension powder 
almost instantaneously dissolved and maintained a constant level over the course of the one 
hour study for both drugs. The NanoCluster samples had dissolution kinetics in between the 
two controls but were statistically more similar to the nanoparticle suspensions.
For budesonide, there appeared to be a minor correlation between NanoCluster milling time 
and dissolution rate. The NanoCluster sample milled for 5 hours appeared to have less drug 
dissolved in the first 15 minutes compared to the NanoCluster sample milled for 10 hours, 
which was lower than the NanoCluster sample milled for 15 hours by a similar margin. 
Differences in these dissolution rates, however, were not statistically significant according to 
a paired T-test. NanoCluster samples milled for 15 hours had a higher dissolution rate than 5 
hour milled NanoClusters up to 30 minutes. For danazol, there did not appear to be any 
differences between the milled NanoCluster samples. There was a small gradual increase 
(about 10%) in concentration with the NanoCluster samples milled for 10 and 15 hours 
showing a similar trend to the increase seen in comparison to the micronized stock. These 
differences again were not significant. Overall, the NanoCluster samples had faster 
dissolution rates compared to the micronized stock and similar to the nanoparticle 
suspension, but differences between the different NanoCluster mill times were not 
significant.
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The next step was to model the dissolution profiles to see if they followed any previous 
models (Table 3 and Fig 7). The Higuchi model is the classical standard and follows a 
dissolution model as seen in Eqn 1, but it was originally developed to describe the transport 
from a thin film into the skin. The Higuchi model is a macroscopic model that does not 
apply to our microscopic system and does not have the same geometry as our system. Thus 
the predicted dissolution profile is far below the observed dissolution profiles (Fig 7)41.
Further refinements of the Higuchi dissolution model were made by Peppas, who included 
multiple geometries including spheres and cylinders as drug release systems. Peppas solved 
for the dissolution from a sphere (Eqn 3). This equation was developed for tablets and 
formulations on a macroscopic scale, and when applied to the microparticles or 
nanoparticles used here, fails in part due to the smaller scale and irregular surface area of the 
NanoCluster system42. The last model used here was developed by Siepmann. This model 
was developed to describe release from several different drug carrier systems including drug 
reservoirs, monolithic solutions, or monolithic dispersions. The monolithic solution, which 
more closely resembles our NanoClusters samples as it is a sphere of homogenously 
dispersed drug with no exterior coating. The full model is the same as the system developed 
by Peppas (Eqn 3). The Siepmann model, however, provides a short time (less than 40% of 
drug released – Eqn 4) and a late time (more than 60% of drug released – Eqn 6) 
approximation for drug release. Again, using this model of late time approximation as the 
lowest amount of drug measured was 57% released, did not properly model NanoCluster 
dissolution kinetics. The major issue with this model, as with the previous two, is that this 
model targets macroscopic systems such as a tablet or capsule containing drug. As the 
system becomes smaller for micro and nanoparticles, the decreased radius skews the 
equations leading to inaccurate results43. In Fig 7, the Siepmann model is shown to have a 
good fit but that requires falsely inflating of the size of the particle, increasing it by 1000 
fold to achieve this close fit.
Other models offer a better fit that can provide further explanation of this data. There are 
several models with NanoCrystal® technology which is similar to the nanoparticle 
suspension. A model based on two different processing methods: jet milled and 
NanoCrystal® was previously reported40. The reported jet milled product is very similar to 
the micronized stock used here with a median particle size of 3 μm and a distribution where 
90% of the product is between 2 – 10 μm. The jet milled product has a similar size range as 
well to our milled NanoCluster providing a reasonable starting point to model dissolution of 
both the micronized stock and NanoClusters. The reported NanoCrystal® model has almost 
constant dissolution throughout time in the model. The difference in surface areas between 
the jet milled and NanoCrystal® was 8–9 fold. The jet milled model very closely traces our 
micronized stock profile with a slight overestimation but stays within 5% throughout the 
length of the study and model.
The more interesting observation occurs with the milled NanoClusters. Even though the 
NanoClusters have a similar geometric size to the jet milled product they have a similar 
dissolution profile to NanoCrystal® throughout most of the model. The NanoClusters have a 
similar increase in surface area compared to the micronized stock when contrasting the 
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reported modeling of NanoCrystal® compared to the jet milled product. The only difference 
is in the early time frame which may be due to several factors.
One cause that could be simply not enough data points were collected during the early time 
phase (the first ten minutes). Another factor could be the NanoCluster microenvironment as 
illustrated in Fig 8. With the micronized stock and nanoparticle suspension, there may be 
well defined water contact with the free surface of drug particles allowing an approximation 
that sink conditions are maintained at all free surfaces. Because sink conditions can be 
maintained, the concentration profiles in gray are maintained allowing for simple modeling 
of dissolution from the particle surface (Fig 8A and 8C). Since NanoClusters are comprised 
of agglomerated nanoparticles, the space between the nanoparticles could experience a high 
local concentration that approaches or exceeds saturation. Due to the interplay of dissolution 
from adjacent surfaces, local concentration gradients could be affected. This complexity is 
difficult to model and may help explain the differences seen in the early time frame. As the 
particles continue to dissolve, the particles shrink providing a larger space between the 
individual particles thus reducing the impact of impinging concentration profiles allowing 
the model to capture the dissolution more accurately31.
 4. Conclusion
As high as 40% of new pharmaceutical products are poorly water soluble, which in some 
cases can lower their oral bioavailability. One way to potentially increase the bioavailability 
of BCS class II compounds is to increase their dissolution rate. Wet milling either 
budesonide or danazol into nanoparticle agglomerates called NanoClusters yielded faster 
and more complete dissolution compared to micronized drug. NanoClusters had dissolution 
kinetics similar to nanoparticle suspension samples. The increased dissolution kinetics was 
theorized to be from an increase in surface area and not due to a change in crystalline form 
as demonstrated by DSC and PXRD analysis. By processing poorly water soluble drugs into 
NanoClusters, increased dissolution kinetics can be achieved using these high surface area 
micron-sized drug particles without the need for excipients.
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Scanning electron micrographs of budesonide NanoClusters at different milling times; A) 
micronized stock budesonide, B) 5 hour milled NanoCluster powder, C) 10 hour milled 
NanoCluster powder, D) 15 hour milled NanoCluster powder, E) nanoparticle suspension 
powder milled in 0.1% (w/v) Pluronic® F-68 solution. Magnification is 15000x with all 
scales bars being 1 μm and C and E insets including 50000x magnification.
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Scanning electron micrographs of danazol NanoClusters at different milling times; A) 
micronized stock budesonide, B) 5 hour milled NanoCluster powder, C) 10 hour milled 
NanoCluster powder, D) 15 hour milled NanoCluster powder, E) nanoparticle suspension 
powder milled in 0.1% (w/v) Pluronic® F-68 solution. Magnification is 15000x with all 
scales bars being 1 μm and C and E insets including 50000x magnification.
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DSC of budesonide powders. Black solid trace shows micronized budesonide stock, gray 
solid trace shows 5 hour milled NanoCluster powder, gray short dash trace shows 10 hour 
milled NanoCluster powder, gray long dash trace shows 15 hour milled NanoCluster 
powder, and black dash trace shows nanoparticle suspension powder milled in 0.1% (w/v) 
Pluronic® F-68 solution.
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DSC of danazol powders. Black solid trace shows micronized danazol stock, gray solid trace 
shows 5 hour milled NanoCluster powder, black dash trace shows nanoparticle suspension 
powder milled in 0.1% (w/v) Pluronic® F-68 solution, gray short dash trace shows 10 hour 
milled NanoCluster powder, and gray long dash trace shows 15 hour milled NanoCluster 
powder.
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Dissolution of budesonide powders where diamonds show the micronized budesonide stock 
while the dark squares NanoCluster powder milled for 5 hours, triangles show NanoCluster 
powder milled for 10 hours, and light squares show the NanoCluster powder milled for 15 
hours. The circles represent the nanoparticle suspension. All error bars are the standard 
deviations of 3 runs. Stars represent P values < 0.05 for micronized stock compared to 
NanoClusters and nanoparticle suspension.
Kuehl et al. Page 18














Dissolution of danazol powders where diamonds show the micronized danazol stock while 
the dark squares NanoCluster powder milled for 5 hours, triangles show NanoCluster 
powder milled for 10 hours, and light squares show the NanoCluster powder milled for 15 
hours. The circles represent the nanoparticle suspension. All error bars are the standard 
deviations of 3 runs. Stars represent P values < 0.05 for micronized stock compared to 
NanoClusters and nanoparticle suspension.
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Dissolution models are shown and how they best represent the dissolution of micronized 
stock and NanoClusters. Models included are the classical Higuchi in dotted gray and late 
time approximation based on the Peppas and Siepmann modified Higuchi model in dotted 
black as macroscopic models. Also included are microscopic models of micronized drug in 
solid gray and Nanocrystal® in solid black. Included in gray squares is the micronized stock 
data and in black squares is the NanoCluster data.
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A shows the dissolution profiles surrounding the individual micronized stock particles. B 
shows a representation of the NanoClusters with an enlargement showing the 3 starred 
particles and how the dissolution profiles interact and may have a certain combinatorial 
effect. C shows the individual nanoparticles of the nanoparticle suspension and their 
individual dissolution profiles.
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Chromatograms of budesonide micronized stock in black and 10 hour milled NanoClusters 
in gray showing the drug peak and degradation peak (retention time = 4.73 min and 2.72 
min). The inset shows an enlarged view of the chromatograms illustrating the difference in 
the micronized stock with no degradant peak and milled NanoCluster samples with a 
degradant peak.
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Chromatograms of danazol micronized stock in black and 10 hour milled NanoClusters in 
gray showing the drug peak and degradation peak (retention time = 8.62 min and 6.34 min). 
The inset shows an enlarged view of the chromatograms illustrating the difference in the 
micronized stock with no degradant peak and milled NanoCluster samples with a degradant 
peak.
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PXRD of budesonide powders where micronized budesonide is the top trace followed by 5 
hour milled NanoCluster, 10 hour milled NanoCluster, 15 hour milled NanoCluster, and 
nanoparticle suspension in descending order.
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PXRD of danazol powders micronized danazol is the top trace followed by 5 hour milled 
NanoCluster, 10 hour milled NanoCluster, 15 hour milled NanoCluster, and nanoparticle 
suspension in descending order.
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Table 3
Dissolution models along with the governing equations to model dissolution of micronized stock and 
NanoClusters. Includes description of variables and assumptions.
Model Main Dissolution Equation Other Equations Variables Assumptions
Classical Higuchi41
Mt = k t Eqn 1 k = A 2CiDCs Eqn 2
Ci = initial 
concentration
Cs = drug 
solubility
A = surface 
area

















Higuchi – Peppas 
Derivation 42















a = radius of 
sphere


















4 Short term 
approx. only 














Mt = − 3D
R2
Cs
Ci t Eqn 5
Monolithic Dispersion







Ci = initial 
concentration
Cs = drug 
solubility
a = radius of 
sphere
D = diffusion 
coefficient















5 Late time 
after 60% of 
drug released
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